Beta Bionics (BBNX) vs OrthoPediatrics (KIDS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OrthoPediatrics (KIDS) has outperformed Beta Bionics (BBNX) over the past year, gaining 77.8% versus a loss of 57.5%. OrthoPediatrics is the larger company by market cap ($828.7 million vs $726.3 million), about 1.1 times the size, while Beta Bionics is growing revenue faster (+53.9% vs +15.4%). OrthoPediatrics converts more of its revenue into profit, with a net margin of -16.8% versus -73.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBNX | KIDS |
|---|---|---|
| Share price | $13.36 | $31.74 |
| Market cap | $726.34M | $828.75M |
| 1-day change | +0.30% | -2.37% |
| YTD return | -56.15% | +78.72% |
| 1-year return | -57.48% | +77.82% |
| 5-year return | — | -45.40% |
| EPS (TTM) | $-1.83 | $-1.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $100.25M | $236.35M |
| Revenue growth (YoY) | +53.94% | +15.45% |
| Net income (latest FY) | $-73.20M | $-39.65M |
| Gross margin | 55.40% | 73.05% |
| Operating margin | -71.50% | -16.60% |
| Net margin | -73.02% | -16.78% |
| 52-week high | $32.71 | $34.53 |
| 52-week low | $8.80 | $14.42 |
| Distance from 52-week high | -59.16% | -8.08% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +87.87% | +6.74% |
| Average volume | 1.21M | 274.74K |
| Shares outstanding | 54.37M | 26.11M |
| Employees | 420 | 602 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KIDS has outperformed BBNX by 135.3 percentage points over the past year.
- OrthoPediatrics is more profitable, keeping -16.8 cents of every revenue dollar as net income versus -73.0 cents for Beta Bionics.
- Beta Bionics grew revenue faster in its latest fiscal year (+53.94% vs +15.45%).
About Beta Bionics
BBNX stock →Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
Health Care · Medical/Dental Instruments · 420 employees
About OrthoPediatrics
KIDS stock →OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products.
Health Care · Medical/Dental Instruments · 602 employees
BBNX vs KIDS FAQ
Which is bigger, Beta Bionics or OrthoPediatrics?
OrthoPediatrics (KIDS) is larger, with a market capitalization of $828.75M compared with $726.34M for Beta Bionics (BBNX).
Which stock has performed better over the past year, BBNX or KIDS?
KIDS returned +77.82% over the past 12 months, compared with -57.48% for BBNX (price return, excluding dividends). Past performance does not predict future results.
Are Beta Bionics and OrthoPediatrics in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.